CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is being registered in developing mRNA vaccines against cancer, but this progress has come up against a wall of misinformation that could thwart the prospects of this promising intervention. Most people first heard about mRNA vaccines during the Covid-19 pandemic when these vaccines were widely used to bring the pandemic under control. However, misinformation soon spread that these vaccines were not only accelerating cancer rates but also causing cancer to be “turbo-charged.” Social media was awash with stories of “turbo cancer” starting in 2021 and mainstream media caught on the following year. Enormous strides have been made in the quest to develop viable mRNA vaccines against cancer. For example, at least 120 clinical trials hold promise in helping the scientific community combat cancer using these vaccines. One notable study shows mRNA vaccination can increase survival times in patients with glioblastoma by enabling the immune system to remain active inside the tumors and yet without this treatment, glioblastoma tumors couldn’t be reached by cancer-fighting immune cells. According to Boatman, such progress is at risk of not being taken up by patients due to the infodemic about turbo cancer. Treatments can only be useful if the public is willing to use them, and the misinformation spreading about mRNA vaccines isn’t helping this promising field of research to reach its full potential. Public health officials need to take on this threat and proactively feed the public the right information so that all proven treatment approaches can be leveraged in the fight against diseases like cancer. Today the misinformation infodemic could be targeting mRNA vaccines, tomorrow it could affect other therapy approaches like the fields in which companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are active. 

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (https://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $2.71, up 7.7535%, on 16,334 volume. The average volume for the last 3 months is 33,605 and the stock's 52-week low/high is $2.0573/$34.7988.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - Misinformation Could Thwart the Potential of Cancer Vaccines
• Fewer Men Undergo Cancer Screening, Study Shows
• TinyGemsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

Disseminated on behalf of Nevada Organic Phosphate Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT).

• A landmark Phase III trial published in The Lancet demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation
• Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida
• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) implemented some cohesion beyond pharmaceuticals in November 2025 with the acquisition of Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform

For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral exposure mattered, but how much it mattered over a patient’s lifetime. A landmark study published in The Lancet in December 2025 offered some of the clearest evidence yet, and the findings are beginning to influence how cancer treatment infrastructure is being planned.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice.

Alongside internal development, LIXTE has pursued selective strategic actions that extend its capabilities beyond drug development, supporting its evolution into a platform-oriented oncology company spanning both pharmaceutical and technology-driven approaches.

The company is headquartered in Boca Raton, Florida.

Portfolio

LB-100 (PP2A Inhibitor Platform)

LIXTE’s lead clinical candidate, LB-100, is a proprietary small-molecule inhibitor of protein phosphatase 2A (PP2A) designed to enhance the activity of chemotherapy and immunotherapy. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Ongoing trials include combinations of LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combination therapy with chemotherapy in advanced soft tissue sarcoma. These studies are being conducted in collaboration with leading academic cancer centers and industry partners, reflecting LIXTE’s emphasis on externally validated clinical execution.

Radiotherapy Platform Expansion (Liora Technologies)

In November 2025, LIXTE expanded beyond pharmaceuticals with the acquisition of Liora Technologies Europe Ltd., adding an electronically controlled proton therapy platform known as the LiGHT System. This acquisition established LIXTE’s entry into radiotherapy, complementing its drug development activities and creating optionality for future recurring revenue models tied to jointly operated treatment centers.

Market Opportunity

LIXTE is targeting cancers where existing therapies show limited durability due to resistance, toxicity constraints, or suboptimal patient response. Chemotherapy and immunotherapy are widely applicable across tumor types but remain constrained by these factors, creating an opportunity for approaches that improve efficacy without proportionally increasing toxicity.

The company’s clinical programs focus on ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, indications characterized by high unmet need and limited effective treatment options. Rather than reshaping oncology care, LIXTE is developing LB-100 to augment existing therapies, an approach that could support wider clinical use within established treatment pathways.

Leadership Team

Geordan Pursglove, Chairman, President and Chief Executive Officer, is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, capital markets, strategic growth initiatives, and operational leadership across both public and private companies. His background includes leadership roles across technology, logistics, customer experience, sports, and marketing, with a focus on scaling organizations, raising capital, and executing transformative strategies.

Bas van der Baan, Chief Scientific Officer, has more than 20 years of experience in biotechnology with a concentration in oncology and diagnostics. He previously served as Chief Clinical and Business Development Officer at Agendia, where he played a key role in initiating and executing clinical trials that supported the commercialization of precision molecular oncology diagnostics in both the U.S. and Europe.

Peter Stazzone, Chief Financial Officer, brings over two decades of financial management experience across publicly traded and privately held companies. His background includes leading capital raises, mergers and acquisitions, financial controls, and public company reporting, with prior CFO roles at companies including Beyond Commerce, Strainz, and Voice Telecom.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), closed Tuesday's trading session at $2.7, up 1.5038%, on 29,371 volume. The average volume for the last 3 months is 27,816 and the stock's 52-week low/high is $0.64/$6.26.

Recent News

• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) - Landmark Proton Therapy Data Changes the Conversation; LIXTE Saw It Coming
• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape
• Investing in Innovation: Evaluating the Clinical and Commercial Potential of LB-100 and Liora's Proton Therapy

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) announced the filing of its Form 10-K for the year ended Dec. 31, 2025, highlighting progress across its clinical-stage pipeline and HOPE Therapeutics operations, including advancing two drug candidates toward FDA approval and opening its first HOPE Therapeutics clinics focused on neuroplastic care. The company reported a reduced operating loss of $16.2 million, down from $18.5 million in 2024, alongside lower research and development and general and administrative expenses, and ended the year with approximately $7.8 million in cash, which management believes will support operations through the end of 2026.

To view the full press release, visit https://ibn.fm/ueppM

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Tuesday's trading session at $2.13, up 20.339%, on 1,577,609 volume. The average volume for the last 3 months is 673,846 and the stock's 52-week low/high is $1.58/$3.84.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - InvestorNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Files 2025 Form 10-K And Highlights Operational Progress
• BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product
• PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Guidance Supporting NDA Review For NRX-100

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Electric cars sitting idle in driveways and parking lots could help stabilize power networks by sending electricity back into the grid during peak consumption hours, yet this vehicle-to-grid concept hasn’t moved beyond small tests across the United States. New research from North Carolina State University identifies why the technology with clear benefits for drivers and utilities alike remains mostly theoretical. The basic idea is pretty straightforward. Cars spend most of their time parked, and battery-powered vehicles essentially amount to energy storage on wheels that could discharge power when demand spikes or renewable sources go dark. This patchwork blocks the large-scale deployment needed to make economics work. Solving adoption requires unified technical requirements and connection protocols across regions, Kim argues. Until jurisdictions align their rules, the technology capable of stabilizing electricity networks while cutting vehicle ownership expenses will stay trapped in isolated experiments instead of reaching mass deployment. The research, authored by Crystal Soderman from University of Colorado Denver alongside Jen Yip from North Carolina State and Manish Shirgaokar from Colorado Denver, appears in the journal Utilities Policy. Perhaps businesses like Massimo Group (NASDAQ: MAMO) could nudge utilities to give this matter a more than cursory look so that the prospects of the concept can be leveraged for the benefit of all parties. 

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Tuesday's trading session at $1.01, up 5.2083%, on 182,767 volume. The average volume for the last 3 months is 178,736 and the stock's 52-week low/high is $0.85/$5.59.

Recent News

• Massimo Group (NASDAQ: MAMO) - Why V2G Technology Uptake Is Not Happening Quickly
• A Quiet War is Brewing Between AC and DC Current in Electric Vehicles
• EV Sales Continue to Grow in the EU, ACEA Data Shows

American Fusion Inc. (OTC: AMFN)

The QualityStocks Daily Newsletter would like to spotlight American Fusion Inc. (OTC: AMFN).

American Fusion (OTC: AMFN) is participating in key industry events, including the 17th International Workshop on Anomalies in Hydrogen Loaded Metals (IWAHLM-17), held March 24-26, 2026 in Bergamo, Italy, and the Applied Power Electronics Conference (APEC), taking place March 22-26, 2026 in San Antonio, Texas. The engagements bring together researchers, engineers and industry participants focused on hydrogen-metal systems, power electronics and advanced energy technologies, and are part of the company’s ongoing efforts to remain involved in technical discussions, monitor developments across related fields and build relationships within the broader energy and infrastructure ecosystem.

To view the full press release, visit https://ibn.fm/NSdY5

American Fusion Inc. (OTC: AMFN) is an advanced energy platform company focused on building a scalable, infrastructure-grade fusion energy business through its wholly owned subsidiary, Kepler Fusion Technologies. Following a completed reverse merger with Kepler, the company has repositioned itself around the development and long-term commercialization of deployable fusion power systems designed for real-world industrial and infrastructure use rather than experimental research programs.

The company’s strategy centers on pairing proprietary fusion technology with disciplined governance, intellectual property development, and a public-company operating framework intended to support long-duration value creation. Management has emphasized transparency, regulatory readiness, and institutional credibility as foundational elements alongside continued technical progress.

The company is based in Southlake, Texas.

Kepler Texatron™

Through wholly owned subsidiary, Kepler Fusion Technologies, the company is developing the Texatron™ aneutronic fusion platform, a compact, pulsed fusion system engineered specifically for commercial and infrastructure-grade deployment. Unlike steady-state fusion concepts that prioritize laboratory demonstration, the Texatron™ operates in controlled cycles designed to support modular scalability, redundancy, and distributed installation across multiple end markets.

The platform is optimized around a Deuterium–Helium-3 fuel pathway that enables direct electrical energy conversion, reducing reliance on traditional steam cycles and minimizing neutron-related material degradation. This design supports a smaller physical footprint and greater flexibility for deployment in grid-constrained or mission-critical environments such as data centers, industrial facilities, defense installations, and remote locations.

Kepler’s commercialization model is structured around a Power-as-a-Service approach under which the company intends to retain ownership of its fusion units and sell electricity to customers under long-term contractual arrangements. This infrastructure-oriented model is designed to align system deployment with predictable, recurring revenue while allowing for fleet-based scaling over time. The platform is supported by a broad and expanding intellectual property estate encompassing reactor architecture, energy conversion systems, control technologies, manufacturing processes, and deployment methodologies.

Market Opportunity

U.S. electricity demand has re-entered a period of sustained growth following nearly two decades of relative stagnation, according to data from the U.S. Energy Information Administration. After years in which efficiency gains and structural economic shifts largely offset population and economic growth, electricity consumption has increased meaningfully since 2020 and is forecast to continue rising through at least the middle of the decade.

Recent and projected growth is being driven primarily by the commercial and industrial sectors, with data centers, advanced manufacturing, and other power-intensive operations accounting for a disproportionate share of incremental demand. These segments tend to require continuous, non-intermittent electricity supply, placing increased pressure on existing generation and transmission infrastructure.

This shift underscores a growing need for reliable baseload power sources that can be deployed without extensive new transmission build-out and that align with emissions-reduction objectives. Fusion-based energy systems designed for distributed, infrastructure-grade deployment represent a potential long-term solution for meeting rising demand in environments where reliability, resilience, and scalability are critical.

Leadership Team

Richard Hawkins, Chairman and Chief Executive Officer, has overseen the company’s strategic reset, corporate restructuring, and transition toward an advanced fusion energy platform, with responsibility for governance, capital markets strategy, and long-term corporate development.

Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies, brings extensive experience in energy systems and commercialization strategy and leads the development, validation, and deployment roadmap for the Texatron™ fusion platform, as well as Kepler’s intellectual property and operating model.

American Fusion Inc. (OTC: AMFN), closed Tuesday's trading session at $0.056, up 17.1548%, on 9,691,466 volume. The average volume for the last 3 months is 22,705,800 and the stock's 52-week low/high is $0.000001/$0.08.

Recent News

• American Fusion Inc. (OTC: AMFN) - https://www.investorbrandnetwork.com/newsarticle/?qmodStoryID=8506959496064742
• InvestorNewsBreaks – American Fusion Inc. (OTC: AMFN) Appoints Michael Carlson Chief Financial Officer
• GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) To Begin Trading As American Fusion Inc. Under AMFN Ticker

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present its Deciparticle (TM) nanomedicine platform and clinical pipeline at BIO-Europe Spring 2026 on March 25, where it has been selected as a presenting company. The company will highlight its next-generation drug delivery technology along with two lead candidates, Sapu003 (Everolimus for Injection), currently in Phase 1 trials, and Sapu006 (Docetaxel for Injection), entering Phase 1, as it seeks strategic partnerships to advance development and commercialization.

To view the full press release, visit https://ibn.fm/Slq47

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Tuesday's trading session at $0.04, up 6.1008%, on 673,912 volume. The average volume for the last 3 months is 432,110 and the stock's 52-week low/high is $0.015/$0.11.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) To Present Deciparticle Platform And Pipeline At BIO-Europe Spring 2026
• InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Subsidiary Sapu Nano To Present Everolimus Toxicology Data At SOT 2026
• BioMedNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured In NetworkNewsAudio On Biotech M&A Trends

CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF)

Disseminated on behalf of CMX Gold & Silver Corp., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF).

Disseminated on behalf of CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) and may include paid advertising.

• CMX Gold & Silver Corp., an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, sees compelling prospects for unexplored areas of the project, magnified by the growing value of silver
• According to J.P. Morgan Global Research, silver prices are projected to average $81/oz in 2026, double their average in 2025, encouraging aggressive exploration of the historically productive but largely unexplored site
• In January 2026, the company commenced a non-brokered private placement financing for aggregate gross proceeds of up to CAN$2,000,000

CMX Gold & Silver (CSE: CXC) (OTC: CXXMF) , an exploration-stage company advancing the historic Clayton Silver Mine in Idaho, recognizes that global demand and geopolitical factors are further boosting silver prices. To capitalize on this growth, the company is moving forward with the exploration of its flagship Clayton Silver project in Idaho, a 1,028-acre property with 29 patented mining claims, 2 patented mill sites, and 20 unpatented claims ( https://ibn.fm/6SkLE ).

CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) is advancing the historic Clayton Silver Mine in Idaho, a past-producing underground operation with a long operating history and significant remaining exploration potential. The company holds a 100% interest in the project through its wholly owned U.S. subsidiary and has positioned the asset as its sole operational focus, allowing management to concentrate technical, financial, and strategic efforts on a single, well-documented silver system.

Clayton was mined for more than five decades but was never systematically explored using modern geophysical or drilling techniques. Historical operators followed known mineralization to supply a relatively small mill and did not pursue broader resource definition or deeper targets, leaving substantial portions of the mineralized system only partially mined or entirely untested. CMX has compiled extensive historical records and mine data that now form the foundation for a modern reassessment of the property.

As CMX advances Clayton during a period of sustained supply deficits and rising industrial demand for silver, the company does so with a high degree of internal alignment. As of December 2025, management, directors, and associated shareholders collectively held approximately 70% of the company’s issued and outstanding shares, underscoring a long-term commitment to the project’s development.

The company is headquartered in Calgary, Alberta.

The Clayton Silver Project

The Clayton Silver Project is CMX’s 100%-owned flagship asset, located in the Bayhorse Mining District of central Idaho, approximately 30–40 kilometers south-southwest of Challis. The property comprises a 1,028-acre land package, including 29 patented mining claims and two patented mill sites (approximately 562 acres) and 20 unpatented claims (approximately 466 acres). The patented claims provide surface ownership rights, carry no government royalties, and do not require drilling permits.

Historic Production and Development

The Clayton Silver Mine operated from 1935 to 1986 and was one of the most active underground mines in the district. Recorded production totaled approximately 7.0 million ounces of silver, along with lead, zinc, copper, and minor gold, from an estimated 2.15 million tonnes of ore, representing an illustrative gross metal value of approximately $660 million at $75/oz silver. Underground development reached eight levels to 1,100 feet, with nearly 19,700 feet of workings, and partially mined two tabular ore bodies known as the South and North Ore Bodies.

Geological Potential

Mine records and historical drilling indicate that mineralization remains open to depth and along strike. Notably, drill hole 1501-A intersected 22 feet of high-grade polymetallic mineralization at approximately 1,425 feet, confirming continuity below the deepest historic workings. CMX has determined that little modern geophysical work or systematic exploration drilling was conducted during the mine’s operating life.

Planned Exploration Programs

Beginning in spring 2026, CMX plans to conduct a comprehensive geophysical program over the historic mine and surrounding structures, including a 3-D Direct Current Induced Polarization (DCIP) survey and a Magnetotelluric (MT) survey. These surveys are intended to delineate known structures, identify extensions of partially mined ore bodies, and evaluate deeper sources of mineralization, with follow-up diamond drilling planned to test priority targets.

Surface Stockpile Opportunity

CMX also controls a surface stockpile estimated to exceed 1.0 million tonnes of mineralized material that was historically mined but not processed. Testing conducted in 2014 and TOMRA ore-sorting trials in 2022 and 2023 demonstrated that X-Ray Transmission (XRT) sorting increased silver grades by approximately 6.4 times and lead and zinc grades by approximately seven times, while recovering more than 70% of contained metals into a high-grade concentrate representing about 10% of the original mass.

Market Opportunity

Silver is a critical industrial metal with more than 10,000 documented uses and is valued for its electrical conductivity, thermal conductivity, reflectivity, corrosion resistance, and antimicrobial properties. Global silver demand is estimated at approximately 1.19 billion ounces, while global mine production is approximately 830 million ounces, resulting in a persistent supply deficit driven largely by industrial consumption across electronics, solar photovoltaics, electric vehicles, medical applications, catalysts, and battery technologies.

These supply-demand dynamics have been reflected in pricing. In January 2026, silver exceeded $80 per ounce, up 160% over the prior 12 months. This pricing underscores the impact of sustained physical deficits, declining mine supply since 2016, and rising industrial demand tied to green energy, electrification, and emerging technologies such as artificial intelligence. With approximately 70% of global silver production sourced as a byproduct of other metal mining, the industry’s ability to respond quickly to higher prices remains constrained, reinforcing the structural nature of the current market imbalance.

Leadership Team

Jan M. Alston, President and Chief Executive Officer, has more than four decades of experience in public junior natural resource companies across mining, oil and gas, and corporate finance. A trained lawyer, he practiced business law and securities regulation before serving as co-founder, President, and CEO of Purcell Energy Ltd., and later as CEO of Tenergy Ltd., both publicly listed energy companies that were ultimately sold in significant transactions. Since 2011, he has led the advancement of CMX’s Clayton Silver Project.

Glen R. Alston, Chief Financial Officer, has more than 30 years of experience in senior executive and management roles with public junior mining companies. His background includes corporate finance, stock exchange listings, corporate development, project management, and accounting and audit oversight, and he played a key role in CMX’s acquisition of the Clayton Silver Project.

Richard T. Walker, P.Geo., Consulting Geologist, is a Professional Geologist with more than 30 years of exploration experience across Canada, the United States, and South America. He has managed exploration programs for precious and base metals in a wide range of geological settings and has served as President of Dynamic Exploration Ltd. since 1996, providing independent geological consulting services to the mining industry.

Qualified Person Statement – All scientific and technical information contained in the CMX Gold & Silver Corp. Market Awareness Profile (MAP) has been reviewed and approved by Richard Walker, M.Sc. (Geology), P.Geo., independent consulting geologist considered a Qualified Person for the purposes of NI 43-101.

CMX Gold & Silver Corp. (OTC: CXXMF), closed Tuesday's trading session at $0.24, even for the day. The average volume for the last 3 months is 7,720 and the stock's 52-week low/high is $0.0001/$0.4.

Recent News

• CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) - CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Sees Important Geological Indicators for Advancing Clayton Silver Project Exploration
• RockBreaks - CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Advances Exploration Strategy at Flagship Idaho Silver Project
• RockBreaks - CMX Gold & Silver Corp. (CSE: CXC) (OTC: CXXMF) Positions to Restart Exploration at High-Grade Idaho Silver Asset

Earth Science Tech Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech Inc. (OTC: ETST).

Earth Science Tech (OTC: ETST) announced the official launch of MyOnlineConsultation.com through MOCTeledoc LLC, a fully integrated doctor network providing technology and clinical staffing solutions to digital health companies, following a beta phase that achieved cash-flow-positive status. The platform supports ETST’s vertically integrated healthcare ecosystem by connecting its prescriber network with compounding pharmacies, including RxCompound and Mister Meds, while offering turnkey telehealth technology, clinical staffing and integrated fulfillment as the company positions MOCTeledoc as a new revenue stream alongside divisions that generated $25.9 million for the nine months ended Dec. 31, 2025.

To view the full press release, visit https://ibn.fm/Pang9

Earth Science Tech Inc. (OTC: ETST) is a strategic holding company that builds value by acquiring and actively managing operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and select consumer markets. The company focuses on controlling interests in subsidiaries where operational oversight, regulatory compliance, and disciplined scaling can drive durable growth.

Since 2022, Earth Science Tech has completed a deliberate transition away from legacy activities and repositioned the organization around healthcare and pharmaceutical operations. That shift has been supported by regulatory alignment, expanding operating capabilities, and the assembly of a diversified portfolio of revenue-generating businesses.

Today, the company’s approach emphasizes execution, capital discipline, and long-term value creation across its operating platforms, with a focus on scaling businesses that can grow sustainably while enhancing shareholder value.

The company is headquartered in Miami, Florida.

Subsidiaries

Earth Science Tech conducts its operations through a portfolio of wholly owned and majority-owned subsidiaries spanning pharmaceutical compounding, telemedicine, healthcare services, real estate development, and direct-to-consumer products.

• RxCompoundStore.com LLC – A fully licensed compounding pharmacy based in Miami, Florida, authorized to fulfill prescriptions across more than 20 U.S. states and Puerto Rico, with ongoing licensure expansion efforts nationwide.
• Mister Meds LLC – A Texas-based compounding pharmacy operating from a 5,000-square-foot facility with advanced sterile and hazardous drug compounding capabilities, acquired to expand production capacity and geographic reach.
• Peaks Curative LLC – A telemedicine referral platform providing asynchronous consultations for Peaks-branded compounded medications, supported by an expanding provider network and recent entry into the veterinary market through Zoolzy.com.
• DOConsultations LLC – An online telehealth platform focused on customized medication formulations, supporting direct-to-patient delivery through partner pharmacies.
• Las Villas Health Care Inc. – A brick-and-mortar and telehealth healthcare provider serving the Spanish-speaking community, offering specialized wellness and sexual health services.
• Avenvi LLC – A diversified real estate development and asset management company overseeing property investments, development projects, and the company’s ongoing share repurchase program.
• MagneChef (80% interest) – A direct-to-consumer retail brand leveraging proprietary intellectual property to develop and market kitchen and cooking-related products, with recent expansion into premium American-made BBQ tools.
• Earth Science Foundation Inc. – A 501(c)(3) nonprofit organization serving as the company’s charitable arm, providing financial assistance for prescription costs to qualified individuals.

Collectively, these subsidiaries provide Earth Science Tech with diversified exposure across regulated healthcare services, digital health platforms, real estate assets, and proprietary consumer brands.

Market Opportunity

Earth Science Tech is primarily positioned within the pharmaceutical compounding and telemedicine markets, both of which are experiencing sustained growth driven by demand for personalized healthcare solutions, expanded access to care, and increasing adoption of remote service models.

The pharmaceutical compounding market continues to benefit from rising demand for customized medications, improved patient adherence, and supply-chain flexibility. According to Grand View Research, the global compounding pharmacies market was valued at approximately $13.1 billion in 2023 and is projected to reach $18.6 billion by 2030, representing a compound annual growth rate of 5.11% from 2024 to 2030. Earth Science Tech’s compounding operations through RxCompoundStore.com and Mister Meds align directly with this expanding market segment.

Telemedicine represents a second core growth vertical for the company, supporting the clinical delivery of pharmaceutical products and healthcare services. According to Fortune Business Insights, the global telemedicine market was valued at $111.99 billion in 2025 and is projected to grow to $532.08 billion by 2034, reflecting a compound annual growth rate of 20.0%, with North America accounting for approximately 48% of market share in 2025. Platforms operated by Peaks Curative and DOConsultations participate directly in this rapidly expanding digital health ecosystem.

Additional exposure to specialty healthcare clinics and real estate development provides diversification alongside the company’s core pharmaceutical and telemedicine operations.

Leadership Team

Giorgio R. Saumat, Chief Executive Officer and Chairman of the Board, is an investor and entrepreneur with more than 20 years of experience investing in, operating, and advising private businesses, including founding CASAU Group, a private equity firm focused on real estate, and POINT96 Consulting, which provides strategic planning services to businesses and accredited investors.

Ernesto L. Flores, Chief Financial Officer, is a financial executive with over a decade of experience in accounting, taxation, and financial management, having held senior roles overseeing compliance and financial operations at logistics and investment firms.

Mario G. Tabraue, President and Chief Operating Officer, brings experience across real estate, maritime operations, and digital infrastructure and was instrumental in acquiring RxCompoundStore.com with the vision of scaling it into a nationally competitive pharmaceutical and telemedicine platform.

Christopher Rose, Chief Technology Officer, is a technology and automation executive who previously led enterprise-wide automation initiatives at a Fortune 100 company, delivering large-scale operational efficiencies and global process automation.

Earth Science Tech Inc. (OTC: ETST), closed Tuesday's trading session at $0.1, even for the day, on 142,250 volume. The average volume for the last 3 months is 35,570 and the stock's 52-week low/high is $0.001/$0.237.

Recent News

• Earth Science Tech Inc. (OTC: ETST) - BioMedNewsBreaks - Earth Science Tech, Inc. (OTC: ETST) Launches MyOnlineConsultation Platform Through MOCTeledoc
• Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care
• Earth Science Tech Inc. (ETST) Is Operating a Diversified Portfolio of Businesses in the Pharmaceutical, Healthcare, Telemedicine and Consumer Markets

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

U.S. federal prosecutors have charged three people linked to AI server producer Super Micro Computer, including one of its founders, with orchestrating the illegal transfer of American AI technology to China, in breach of export regulations. According to the Justice Department, the alleged scheme involved the covert transfer of at least $2.5 billion in advanced server equipment. While prosecutors did not initially identify the company in court filings, Super Micro later confirmed it had been notified of the indictment and said it has cooperated fully with investigators. Officials have not specified which chips were part of the alleged operation, though Nvidia is widely recognized as a leading supplier in the AI chip market. The company reiterated its commitment to complying with export regulations and said it works closely with clients and regulators to ensure compliance. A spokesperson for Nvidia warned that attempts to divert restricted technology are unlikely to succeed, citing strict enforcement measures and a lack of support for systems obtained through illegal channels. Tech firms, such as D-Wave Quantum Inc. (NYSE: QBTS), are likely to be shocked that a cofounder of a company like Super Micro could be indicted on accusations of breaching technology export restrictions. 

About AINewsWire

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Tuesday's trading session at $15.93, off by 2.3299%, on 18,049,955 volume. The average volume for the last 3 months is 23,645,519 and the stock's 52-week low/high is $5.77/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - MissionIRNewsBreaks - Rail Vision Ltd. (NASDAQ: RVSN) Begins Trading On Frankfurt Stock Exchange
• Nvidia Moves to Make AI Agents Go Mainstream
• US Military Admits it is Using AI in Attacks Against Iran

Rail Vision Ltd. (NASDAQ: RVSN)

The QualityStocks Daily Newsletter would like to spotlight Rail Vision Ltd. (NASDAQ: RVSN).

Rail Vision (NASDAQ: RVSN) announced that its ordinary shares have begun trading on the Frankfurt Stock Exchange under the symbol C80, while continuing to trade on the Nasdaq Capital Market under RVSN. The company said the dual listing is expected to enhance visibility and trading liquidity in Europe, broaden its investor base and provide expanded access to European institutional and retail investors.

To view the full press release, visit https://ibn.fm/gMh9m

Rail Vision Ltd. (NASDAQ: RVSN) is an early commercialization-stage technology company developing unique rail-specific detection systems designed to improve safety and operational performance across global railway networks. The company’s products address visibility, hazard detection, and situational awareness challenges, which are critical for preventing collisions, reducing operational risks, and improving overall railway efficiency in diverse and demanding environments.

Rail Vision’s technology combines electro-optical sensors with artificial intelligence to extend real-time awareness along and around rail tracks under a wide range of operating conditions. The company aims to support safer train movement, improve operational reliability, and enhance decision-making for both manned and increasingly automated rail systems.

Rail Vision aims to deliver measurable safety, efficiency, and cost benefits for passenger and freight operators, while contributing to the continued evolution of modern rail infrastructure.

The company is headquartered in Ra’anana, Israel.

Products

Rail Vision offers two primary rail-deployed systems, MainLine and ShuntingYard, designed for distinct operating environments, along with a cloud-based operational intelligence dashboard that extends system functionality through data analysis and reporting.

• The MainLine system provides extended forward-looking visibility of up to 1.2 miles along open rail corridors, enabling real-time detection and classification of obstacles, hazards, and track-related events across a wide range of weather and lighting conditions. Designed for continuous operation, the system delivers real-time alerts that enhance driver awareness, improve safety, and increase operational efficiency.
• The ShuntingYard system detects hazards and provides visibility of up to 200 yards under diverse weather and lighting conditions along rail yards. The system offers front-to-back visual coverage, wide-view coupling cameras, and path-finding capabilities to support safe maneuvering in dense, low-speed operational settings.

Both systems are complemented by visual and acoustic alerts intended to reduce collision risk, minimize operational downtime, and improve efficiency during complex operations.

Rail Vision also offers a cloud-based SaaS intelligence portal that aggregates and analyzes data generated by Rail Vision’s products. This platform is designed to empower operators with the tools they need to efficiently manage their fleets, review historical data, and generate comprehensive reports, ultimately reducing downtime, lowering costs, and integrating Rail Vision’s data outputs with existing or future big data environments.

Additional offerings include system software updates, parts and repairs, support services, and tailored integrations.

Market Opportunity

Rail Vision operates within a growing global market driven by increasing demand for railway safety, operational efficiency, and automation. According to Research and Markets, the train collision avoidance systems market was estimated at approximately $20.3 billion in 2024 and is projected to reach $57.8 billion by 2030, representing a compound annual growth rate of 19.0% over that period. This growth reflects heightened focus on accident prevention, infrastructure modernization, and regulatory emphasis on safety.

In parallel, the global autonomous train market was estimated at $9.82 billion in 2023 and is expected to reach $14.50 billion by 2030, growing at a CAGR of 5.9% from 2024 to 2030, according to Grand View Research. Market trends supporting these opportunities include expansion of global rail networks, rising adoption of artificial intelligence and cloud-based services in railway operations, and increased investment in research and innovation related to AI-enabled rail technologies. Together, these dynamics position Rail Vision within markets that are expanding in both scale and technological sophistication.

Leadership Team

David BenDavid, Chief Executive Officer, is a technology executive with more than 25 years of global experience driving innovation across artificial intelligence, cloud computing, and advanced engineering platforms. Prior to joining Rail Vision, he served as CEO and co-founder of Tensorleap, where he led the development of a deep learning analytics platform focused on transparency and performance in AI model deployment.

Ofer Naveh, Chief Financial Officer, brings more than 20 years of experience in accounting and financial management, including roles at KPMG’s audit practice and in senior finance positions at publicly traded companies in Israel and the United States. He holds a B.A. in Accounting and Business and an M.A. in Law.

Noam Shloper, Chief Operating Officer, has more than 20 years of experience in executive compliance, quality management, and project management across military and commercial high-technology environments. He previously served in senior quality and operations roles at DRS Rada Technologies and Logic Industries and holds a degree in Industrial and Management Engineering.

Doron Cohadier, Vice President of Business Development and Marketing, has over two decades of managerial experience in business development and marketing within advanced technology sectors. His background includes senior leadership roles at Foresight Autonomous Holdings and Elbit Systems, supporting global commercialization of vision and defense technologies.

Amit Klir, Vice President of Research and Development, has extensive experience leading multidisciplinary engineering teams and managing the development of products combining video processing, signal processing, and advanced algorithms. He holds a B.Sc. in Electrical and Computer Engineering with a specialization in digital signal processing.

Rail Vision Ltd. (NASDAQ: RVSN), closed Tuesday's trading session at $8.3, off by 5.467%, on 13,216 volume. The average volume for the last 3 months is 41,655 and the stock's 52-week low/high is $3.66/$29.571.

Recent News

• Rail Vision Ltd. (NASDAQ: RVSN) - MissionIRNewsBreaks - Rail Vision Ltd. (NASDAQ: RVSN) Begins Trading On Frankfurt Stock Exchange
• TechMediaBreaks - Rail Vision Ltd. (NASDAQ: RVSN) Completes MainLine System Proof of Concept In India
• Rail Vision Ltd. (NASDAQ: RVSN) Strengthens Commercial Momentum with Next Phase of Israel Railways Collaboration

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSXV: UCU) (OTCQX: UURAF) announced it has executed a memorandum of understanding dated March 16, 2026 with Vulcan Elements Inc. to collaborate on developing a domestic rare earth magnet supply chain for defense and commercial applications, with plans for Ucore to supply NdPr oxide and Dy oxides at commercial scale beginning in 2027. The collaboration links Ucore’s separation platform in Ontario and planned Louisiana Strategic Metals Complex with Vulcan’s North Carolina manufacturing operations, as both companies work toward advancing production, technical specifications and a longer-term commercial supply agreement.

To view the full press release, visit https://ibn.fm/a2C7a

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Tuesday's trading session at $3.5, off by 3.5813%, on 659,736 volume. The average volume for the last 3 months is 301,850 and the stock's 52-week low/high is $0.65/$10.69.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - DefenseNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Signs MOU With Vulcan Elements To Develop Rare Earth Magnet Supply Chain
• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Key Federal Milestone for RapidSX Platform
• EnergyNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Provides Update on Samarium and Gadolinium Supply Initiative

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

• Soligenix is entering a pivotal period marked by several anticipated clinical readouts and milestones expected throughout 2026.
• At the heart of the Zacks analysis is HyBryte(TM), which Soligenix is evaluating in the Phase 3 FLASH2 study for the treatment of CTCL.
• Beyond HyBryte, the report also points to progress involving SGX945, or dusquetide, for Behçet’s disease.

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Tuesday's trading session at $1.17, off by 3.3058%, on 121,480 volume. The average volume for the last 3 months is 135,729 and the stock's 52-week low/high is $1.02/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach
• InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advances Orphan Drug Strategy With HyBryte In Rare Skin Cancer
• InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting